Xtant Medical Holdings, Inc. (XTNT) Income Statement
XTNT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsXTNT revenue and net income
Where XTNT's revenue goes
2025Each bar shows an amount and its share of revenue. XTNT kept 3.7% of revenue as net income.
XTNT profit margins
XTNT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +14.2% | +32.2% | +20.2% | +8.5% |
| Gross profit | +23.5% | +37.9% | +19.6% | +8.0% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XTNT quarterly EPS vs estimates
Xtant Medical beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 9, 2026.
XTNT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.6M | $90.0M |
| Cost of revenue | $49.7M | $49.1M | $35.8M | $25.8M | $22.8M | $18.9M | $22.2M | $28.7M | $32.5M | $27.7M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M | $34.4M | $42.5M | $43.5M | $50.1M | $62.3M |
| Research & development | $2.1M | $2.4M | $1.3M | $915,000 | $870,000 | $657,000 | $932,000 | $1.7M | $2.4M | $3.4M |
| Sales, general & admin | $74.9M | $77.9M | $64.3M | $38.0M | $35.5M | $34.5M | $43.8M | $45.1M | $55.8M | $60.1M |
| Total operating expenses | $77.0M | $80.3M | $65.6M | $38.9M | $36.3M | $35.1M | $44.8M | $50.9M | $63.8M | $68.4M |
| Operating income | $7.3M | −$12.1M | −$10.2M | −$6.8M | −$3.9M | −$751,000 | −$2.4M | −$60.1M | −$37.8M | −$7.5M |
| Interest income | $94,000 | $0 | $164,000 | $31,000 | $0 | — | $5.8M | $10.0M | $14.5M | $11.5M |
| Interest expense | $3.7M | $4.2M | $2.9M | $1.7M | $995,000 | $6.0M | $5.8M | $10.1M | $14.7M | $12.3M |
| Income before taxes | $7.0M | −$16.3M | −$1.0M | −$8.4M | −$4.8M | −$6.7M | −$8.1M | −$70.1M | −$52.4M | −$19.4M |
| Income taxes | $2.0M | $187,000 | −$1.7M | $69,000 | $995,000 | $296,000 | $98,000 | $124,000 | $14.6M | $50,362 |
| Net income | $5.0M | −$16.4M | $660,000 | −$8.5M | −$4.8M | −$7.0M | −$8.2M | −$70.1M | −$52.4M | −$19.5M |
| EBITDA | $15.9M | −$7.9M | $5.1M | −$5.4M | −$2.5M | $1.3M | $792,000 | −$53.4M | −$29.3M | $61,434 |
| EPS (diluted) | $0.04 | −$0.09 | $0.01 | −$0.10 | −$0.07 | −$0.49 | −$0.62 | −$1.39 | −$34.07 | −$16.93 |
| Gross margin | 62.9% | 58.2% | 60.8% | 55.4% | 58.8% | 64.5% | 65.7% | 60.2% | 60.6% | 69.2% |
| Operating margin | 5.4% | −10.3% | −11.1% | −11.7% | −7.0% | −1.4% | −3.6% | −83.2% | −45.8% | −8.4% |
| Net margin | 3.7% | −14.0% | 0.7% | −14.6% | −8.8% | −13.2% | −12.7% | −97.1% | −63.4% | −21.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.0M | $20.9M | $32.4M | $33.3M | $35.4M | $32.9M | $31.5M | $27.9M | $29.9M | $27.9M | $28.1M | $25.0M |
| Cost of revenue | $9.7M | $8.9M | $14.6M | $11.3M | $11.1M | $12.7M | $15.5M | $11.6M | $11.4M | $10.6M | $11.0M | $9.7M |
| Gross profit | $13.3M | $12.0M | $17.8M | $22.0M | $24.3M | $20.2M | $16.0M | $16.3M | $18.6M | $17.3M | $17.1M | $15.3M |
| Research & development | $695,000 | $435,000 | $459,000 | $634,000 | $566,000 | $443,000 | $522,000 | $701,000 | $636,000 | $527,000 | $492,000 | $490,000 |
| Sales, general & admin | $16.8M | $14.5M | $18.2M | $18.8M | $19.1M | $18.7M | $17.4M | $19.4M | $20.9M | $20.2M | $20.5M | $18.2M |
| Total operating expenses | $22.5M | $14.9M | $18.7M | $19.5M | $19.7M | $19.2M | $17.9M | $20.1M | $21.5M | $20.8M | $31.9M | $18.7M |
| Operating income | −$9.2M | −$2.9M | −$944,000 | $2.5M | $4.6M | $1.1M | −$1.9M | −$3.8M | −$2.9M | −$3.5M | −$3.8M | −$3.4M |
| Interest income | $1,000 | $219,000 | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $16,000 | $48,000 |
| Interest expense | $542,000 | $599,000 | $718,000 | $904,000 | $1.0M | $1.0M | $1.1M | $1.2M | $992,000 | $835,000 | $818,000 | $760,000 |
| Income before taxes | −$9.3M | −$3.1M | $1.6M | $1.6M | $3.8M | $33,000 | −$3.1M | −$5.0M | −$3.8M | −$4.3M | −$3.7M | $6.9M |
| Income taxes | $73,000 | $27,000 | $1.5M | $257,000 | $255,000 | −$25,000 | $21,000 | $62,000 | $36,000 | $68,000 | — | −$2.3M |
| Net income | −$9.4M | −$3.1M | $57,000 | $1.3M | $3.5M | $58,000 | −$3.2M | −$5.0M | −$3.9M | −$4.4M | −$4.3M | $9.2M |
| EBITDA | −$8.3M | −$1.9M | $4.1M | $3.6M | $6.0M | $2.2M | −$862,000 | −$2.7M | −$1.8M | −$2.5M | — | $8.6M |
| EPS (diluted) | −$0.07 | −$0.02 | −$0.01 | $0.01 | $0.03 | $0.01 | −$0.01 | −$0.04 | −$0.02 | −$0.02 | −$0.03 | $0.07 |
| Gross margin | 57.9% | 57.3% | 54.9% | 66.1% | 68.6% | 61.5% | 50.8% | 58.4% | 62.1% | 62.1% | 61.0% | 61.3% |
| Operating margin | −39.8% | −14.0% | −2.9% | 7.6% | 13.1% | 3.2% | −6.0% | −13.5% | −9.8% | −12.4% | −13.5% | −13.5% |
| Net margin | −40.9% | −14.8% | 0.2% | 3.9% | 10.0% | 0.2% | −10.0% | −18.0% | −12.9% | −15.8% | −15.3% | 36.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XTNT's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XTNT financial results
In fiscal year 2025 (ended December 31, 2025), Xtant Medical reported revenue of $133.9 million, up 14.2% from the year before. It had net income of $5.0 million, a net profit margin of 3.7%. Diluted earnings per share came to $0.04. Over five years revenue grew at an average rate of 20.2% a year.
See the XTNT stock overview for the latest quote and news, or the XTNT chart for price history and technical indicators.
XTNT income statement FAQ
What is Xtant Medical's annual revenue?
Xtant Medical reported total revenue of $133.9 million for fiscal year 2025, which ended on December 31, 2025. That was up 14.2% from $117.3 million the previous year.
Is Xtant Medical profitable?
Yes. Xtant Medical reported net income of $5.0 million in fiscal 2025, a net profit margin of 3.7%; its operating margin was 5.4%.
What is Xtant Medical's gross margin?
Xtant Medical's gross margin was 62.9% in fiscal 2025: for every $100 of revenue, Xtant Medical kept $63 after the direct cost of its products and services.
How much does Xtant Medical spend on research and development?
Xtant Medical spent $2.1 million on research and development in fiscal 2025, 1.6% of revenue.
How fast is Xtant Medical growing?
Revenue grew 20.2% a year on average over the last five fiscal years, from $53.3 million to $133.9 million.
What are Xtant Medical's earnings per share?
Xtant Medical earned $0.04 per diluted share in fiscal 2025, compared with $-0.09 a year earlier.
When will Xtant Medical report its next earnings?
Xtant Medical is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Xtant Medical's fiscal year end?
Xtant Medical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.